Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | PTGDR2 | Q9Y5Y4 | 9/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | CCR2 | P41597 | 4/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.32 |
| ▸ | ESRRA | P11474 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6332863 | 1.00 | ALDH1A1 (0.34) | ALDH1A1HTTSMN1; SMN2PTGDR2POLB | |
| SCHEMBL6332853 | 0.80 | KDM4E (0.31) | SMN1; SMN2POLB | |
| SCHEMBL6332849 | 0.80 | KDM4E (0.31) | SMN1; SMN2POLB | |
| SCHEMBL6328695 | 0.80 | KDM4E (0.30) | ALDH1A1 | |
| SCHEMBL6328700 | 0.80 | KDM4E (0.30) | ALDH1A1 | |
| SCHEMBL6325414 | 0.79 | ALDH1A1 (0.34) | ALDH1A1PTGDR2 | |
| SCHEMBL6326637 | 0.79 | ALDH1A1 (0.34) | ALDH1A1PTGDR2 | |
| SCHEMBL9115115 | 0.78 | LIPG (0.33) | PTGDR2POLB | |
| SCHEMBL6328144 | 0.77 | ENPP2 (0.34) | ALDH1A1PTGDR2MAPK1ENPP2 | |
| SCHEMBL6328146 | 0.77 | ENPP2 (0.34) | ALDH1A1PTGDR2MAPK1ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6790810-B2 | Tetrazolinone derivatives | NIHON BAYER AGROCHEM K.K. (JP) | 2004-09-14 | — | — | US | disclosed |
| US-20040102635-A1 | Novel tetrazolinone derivatives | YANAGI AKIHIKO (JP) | 2004-05-27 | — | — | US | disclosed |
| US-6624121-B1 | Exemplified by 2-cyano-3-cyclopropyl-1-(3-((4-cyclopropyl-4,5-dihydro-5-oxo-1H-tetrazol-1 -yl)methyl)-2, 4-dichlorophenyl)propan-1,3-dione | NIHON BAYER AGROCHEM K.K. (JP) | 2003-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102635-A1 | Novel tetrazolinone derivatives | CBR1, CBR3, CYP1B1 | ALDH1A1 225/4885HTT 1812/4885SMN1; SMN2 4200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.